Navigation Links
ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company
Date:12/9/2008

de, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 21 of ProMetic's Annual Information Form for the year ended December 31, 2007, under the heading "Risk Factors". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.


'/>"/>
SOURCE Prometic Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ProMetic to present at Merriman Curhan Fords Investor Summit 2008 on September 16th
2. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
3. ProMetic Further Confirms Performance of Prion Capture Resin at the Recovery of Biological Products Conference
4. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
5. Prometic provides information for its Annual and Special Meeting of Shareholders
6. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
7. ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
8. Prometic to present at the American Chemical Society
9. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
10. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
11. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 24, 2014 Research and Markets ... by Product , Research Area & by End User ... offering. In this report, the global ... research areas, and end users. The product segments of ... instruments & consumables, kits, and reagents. The subsegments of ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... growth in the in vitro diagnostic (IVD) test industry, ... Kalorama Information. The healthcare market researcher listed more than 25 ... that could be the future of IVD products. Kalorama details ... industry, The Worldwide Market for In Vitro Diagnostic ...
(Date:10/22/2014)... and BOSTON , Oct. 22, ... a leading global specialty pharmaceutical company, and Rhythm, a ... an exclusive option to acquire Rhythm,s wholly owned subsidiary, ... peptide ghrelin agonist, for the treatment of diabetic gastroparesis ... has completed a successful Phase 2 trial of relamorelin ...
(Date:10/22/2014)... (PRWEB) October 21, 2014 The North ... concerned market North America with analysis and forecast of ... 2013, and is expected to reach $623.6 million by ... 2018. , Browse through the TOC of the North ... of the in-depth analysis provided. This also provides a ...
Breaking Biology Technology:Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4
... SHANGHAI, June 16 /PRNewswire-Asia/ -- ... announced,today that its animal facility in Shanghai has passed ... Sundia management and staff are praised,for providing good facilities ... , The inspection and audit ...
... June 16 /PRNewswire-Asia/ -- Pharmaceutical company Pharmaxis,(ASX: PXS; Nasdaq: ... of its,recently completed international Phase III trial of Bronchitol in ... Cystic Fibrosis,Conference in Brest, France. , ... June by Dr Diana,Bilton of the Royal Brompton Hospital, London. ...
... , DETROIT, June 15 Business, nonprofit and ... the manufacturing sector that includes enacting pro-industry policies and ... investment, and creating new demand through innovation and globalization. ... at The National Summit in Detroit agreed that economic ...
Cached Biology Technology:Sundia's Animal Facility Passed Client and Government Inspection 2Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 2Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 3Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 4Top CEOs Declare America's Manufacturing Sector Requires Pro-Industry Policies, Capital Management and Innovation to Maintain Economic Leadership 2Top CEOs Declare America's Manufacturing Sector Requires Pro-Industry Policies, Capital Management and Innovation to Maintain Economic Leadership 3
(Date:10/16/2014)... a new synthesis of recent research findings to inform ... the two states. , The Ecology and Management ... A Synthesis of the Relevant Biophysical Science and Implications ... by the U.S. Forest Service,s Pacific Northwest Research Station, ... for a synthesis of the large body of scientific ...
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
(Date:10/15/2014)... 2014 Sandata Technologies, LLC, an industry ... care, today announced it released a case study ... Visit Verification™ Solution (EVV™)  for Quality Care Services, ... company founded in 1996 and has five locations ... The study details the challenges facing Quality ...
Breaking Biology News(10 mins):New report synthesizes best available science on management of moist mixed-conifer forests 2New perspectives for development of an RSV vaccine 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... One in eight women in the United States will receive ... is the second leading cause of cancer-related death in women. ... possible treatment for each patient. "Our research shows that ... without getting any treatment at all, other than a lumpectomy," ...
... mobile phone charger at home when you go for ... norm one day as scientists from Nanyang Technological University ... a microchip that uses 30 times less electricity while ... The technology, dubbed PCMOS (probabilistic complementary metal-oxide semiconductor) was ...
... of genetic factors associated with heart attacks has identified ... that appear to increase the risk for early-onset myocardial ... Consortium, based on information from a total of 26,000 ... Genetics and is receiving early online release. ...
Cached Biology News:New test for breast cancer will help guide treatment choices 2Singapore-US scientists first to develop revolutionary microchip that uses 30 times less energy 2Singapore-US scientists first to develop revolutionary microchip that uses 30 times less energy 3International study identifies gene variants associated with early heart attack 2International study identifies gene variants associated with early heart attack 3
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... the Beacon 2000 instrument can be used ... Beacon 2000 Data Manager Software provides the ... directly from the instrument. These data can ... available spreadsheets, such as Microsoft Excel or ...
... This kit allows for quick and reproducible immunoprecipitation ... The system is more reproducible than regular IPs, ... protein A/G agarose without disrupting the agarose bed. ... and Release is reversible, and elution of the ...
... self locking design in ice/water bath ... product number, created to easily match ... availability yet, please order under the ... customer service for assistance. ID clarifier: ...
Biology Products: